Announcement on the Project of Annual Production of 2 billion Solid Preparations by Peak Pharmaceutical
Release time:
2020-08-05
Securities Code: 600668 Securities Abbreviation: Jianfeng Group Announcement No.: Pro 2018-024
Bond Abbreviation: 13 Spike 02 Bond Code: 122344
Announcement of Zhejiang Jianfeng Group Co., Ltd.
on Jianfeng Pharmaceutical's Annual Production of 2 billion Solid Preparations
The Board of Directors and all directors of the Company guarantee that there are no false records, misleading statements or major omissions in the contents of this announcement, and assume individual and joint responsibility for the truthfulness, accuracy and completeness of its contents.
Important Content Note:
l Project Name: 2 billion Pieces of Solid Preparation Project
l Annual Output of Jinxi Production Base of Jianfeng Pharmaceutical Industry Investment Amount: The total planned investment of the project is 501.46 million yuan, and the source of funds is self-raised.
l Special Risk Reminder: The construction period of this project is relatively long. With the continuous advancement of the domestic medical system reform
, the hospital's strict control of drug proportion, sunshine procurement and quantity procurement, secondary bargaining, prescription outflow, etc. continue to deepen, and drug prices show a downward trend. In addition, trade protectionism is on the rise and competition in the international market will become more intense, profitability may be affected and there is a risk that project returns will not meet expectations.
1. Project Investment Overview
According to the company's strategic policy of "strengthening the main business through cooperation and innovation, standardizing science and seeking development", Zhejiang Jianfeng Pharmaceutical Co., Ltd. (hereinafter referred to as "Jianfeng Pharmaceutical Co., Ltd."), a subsidiary of the company, is based on the development strategy of the company and relevant regulations of national pharmaceutical production, in order to further improve the solid preparation production capacity of Jianfeng Pharmaceutical, it is planned to acquire about 78 mu of land on the north side of the existing factory area of Jianfeng Pharmaceutical in Jinhua Economic Development Zone, set up a new preparation factory area, and build a preparation manufacturing platform that meets the requirements of GMP in Europe and America. The construction of the project with an annual output of 2 billion solid preparations in Jinxi Production Base of Jianfeng Pharmaceutical includes two preparation workshops and supporting storage, quality inspection, public works, etc. After the completion of the preparation workshop 1 to form an annual production capacity of 2 billion pieces of solid preparations, while reserving the preparation workshop 2 for later development.
On August 3, 2018, the fifth meeting of the tenth board of directors of the company reviewed and approved the "Proposal on the Project of 2 billion Solid Preparations per Year in Jinxi Production Base of Jianfeng Pharmaceutical", and agreed to invest in the construction of Jinxi Production Base with an annual output of 2 billion solid preparations.
In accordance with the "Shanghai Stock Exchange Stock Listing Rules", "Articles of Association" and other relevant regulations, this project investment is within the decision-making authority of the company's board of directors and does not need to be submitted to the company's shareholders meeting for approval. Related party transactions do not constitute a major asset reorganization as stipulated in the "Administrative Measures for the Major Asset Reorganization of Listed Companies.
Basic Information of 2. Investment Subject
(I) Investment Subject: Zhejiang Jianfeng Pharmaceutical Co., Ltd.
(II) Enterprise Nature: Other Limited Liability Company
(III) Registered Capital: 198.53 million yuan
(IV) Registered Address: legal Representative of (V) Company
, 2nd Floor, X02 Office Quality Inspection Building, No. 58 Gaofan Section, Baitang Downline, Wucheng District, Jinhua City, Zhejiang Province: Jiang Xiaomeng
(VI) Scope of Business: Drug Research and Development and Production (Operating with Valid License); Annual recovery: 8 tons of isopropanol, 76 tons of ethanol, 40 tons of toluene, 409 tons of dichloromethane, and 11 tons of ethyl acetate (operating with valid licenses); imported raw and auxiliary materials for production and scientific research; imported machinery and equipment, instruments and spare parts. (Projects subject to approval according to law can only be operated after approval by relevant departments)
(VII) Financial Situation: As of December 31, 2017, Jianfeng Pharmaceutical has total assets of 1,193.4823 million yuan and net assets of 378.2793 million yuan attributable to owners of the parent company. In 2017, it will realize operating income of 1,337.522 million yuan, operating profit of 50.6395 million yuan and net profit of 37.6413 million yuan attributable to owners of the parent company. Basic Information of
3. Investment Project
(I) Project Name: Jianfeng Pharmaceutical Jinxi Production Base Annual Output of 2 billion Pieces of Solid Preparation Project
(II) to Form Production Scale after Completion: Annual Output of 2 billion Pieces of Solid Preparation
(III) Total Building Area: 63352 m2
Total (IV) Investment: the total investment is 501.46 million yuan, of which the investment in fixed assets is 481.98 million yuan and the working capital is 19.48 million yuan.
(V) construction progress: after the conditions are met, the project construction period is 2 years. The main content of the
(VI) project: the annual output of 2 billion pieces of solid preparations in Jinxi production base of Jianfeng pharmaceutical includes two preparation workshops and supporting storage, quality inspection, public works, etc. After the completion of the preparation workshop 1 to form an annual production capacity of 2 billion pieces of solid preparations, while reserving the preparation workshop 2 for later development.
Impact of 4. Investment Project on Listed Companies
Jianfeng Pharmaceutical has rich experience in preparation research and development, production and sales. This project will further improve the construction of generic preparation production base, promote the upgrading of preparation industry and enhance the comprehensive competitiveness of the company's pharmaceutical sector. Under the background of preparation internationalization and continuous improvement of generic drug consistency evaluation, this project takes international generic drugs as the entry point, which is of great significance to improve the equipment level and manufacturing capacity of Jianfeng pharmaceutical preparations, expand the industrial scale, optimize the product structure and participate in international competition, and will have a positive impact on the future development of the company.
Risk Analysis of 5. Investment Project
(I) Market Risk
The construction period of this project is relatively long. With the continuous advancement of domestic medical system reform, hospitals continue to deepen the 120 of # in strict control of drug proportion, sunshine procurement and quantity procurement, secondary bargaining, prescription outflow, etc, drug prices are on a downward trend; in addition, trade protectionism is on the rise and competition in the international market will become more intense, which may affect profitability, and there is a risk that the project revenue will not meet expectations .
(II) Project Construction and Management Technical Risks
Project is still in the preliminary preparation stage, and land acquisition and environmental assessment have not yet been completed. With the adjustment of relevant national industrial policies and urban planning, the project construction There are certain uncertainties in the content, cycle and process. After the project is completed and put into production, there is a possibility that the expected goals may not be achieved in terms of product process improvement and cost control, and there are certain management and technical risks.
(III) Capital Risk
The total investment of this project is relatively large. The project is invested through self-raised funds. There is uncertainty as to whether the funds can be in place on schedule. The fund raising and credit policy changes in the construction process, The smoothness of financing channels will make the company bear certain capital risks.
(IV) Approval Risk
After the project is reviewed and approved by the board of directors, the project construction still needs to go through compliance procedures such as safety assessment and environmental assessment, and is still in the process of approval. Therefore, whether the project can be finally implemented, There is still some uncertainty about the progress after implementation.
6. Reference Document
Resolution of the Fifth Meeting of the Tenth Board of Directors
is hereby announced.
Zhejiang Jianfeng Group Co., Ltd. Board of Directors
August 3, 2018
More information
Jianfeng Pharmaceuticals ranks among the top 50 creative enterprises in Jinhua
News from our newspaper April 26 is World Intellectual Property Day. Jinhua City released the list of "Top 50 Creative Enterprises" for the first time. Jianfeng Pharmaceutical Company entered the list and ranked second among the enterprises in Jinhua Development Zone. The selection of creative enterprises, the enterprise holds the effective invention patent as the main indicator. Over the years, Jianfeng Pharmaceutical Co., Ltd. has taken "intellectual property rights help enterprise development, and scientific and technological innovation creates a century-old peak" as the company's intellectual property policy. It has actively cooperated with China Pharmaceutical University, Sichuan Institute of Antibiotic Industry, Zhejiang University of Technology, Xiamen University and other units to build a scientific research and innovation platform integrating production, learning and research, and flexibly introduced Academician Wang Guangji and Academician Shan Weiguang with the chief scientist system, according to the direction of enterprise development strategy to carry out scientific research work, and achieved fruitful results. In 2019, Spike Pharmaceuticals applied for 2 invention patents and obtained 5 patent authorizations, including 1 invention. By the end of 2019, Spike Pharmaceuticals had obtained a total of 37 patents (including 2 PCT patents), of which 28 were inventions. In recent years, in order to better integrate with the international market, Jianfeng Pharmaceutical has made a complete patent layout for the new drug DPT under development, and has applied for patent protection in multiple countries through the PCT application channel for core patents, and finally in the high-level United States. And Japan was authorized to lay a solid foundation for the product to enter these two overseas high-end markets. At the same time, around the core patent, applied for the preparation, crystal type patent and obtained the invention patent authorization 5. In addition, pharmaceutical companies have also developed patents for other varieties under research.
2020
07-31
Since the resumption of work after the Spring Festival, on March 17, Yu Jian, general manager of the group company, went to the site of the Huangping project in Guizhou to guide the construction progress of the Huangping project. During his stay in Huang Ping, General Manager Yu Jianhong visited the construction site of the project carefully, interviewed the project leaders of each construction unit respectively, sorted out the installation time of each unit of civil engineering and the completion time of each equipment installation, and required each construction unit to push forward the project progress in strict accordance with the agreed time node. At the same time, in view of the current epidemic prevention and control work and on-site construction safety management, Yu Jianhong also further put forward requirements, hoping to achieve "zero infection, zero accident". On the 18th, Yu Jianhong also conducted a research on the market in Kaili and other surrounding areas together with the marketing personnel of Guizhou Jianfeng Marketing Department, and put forward guiding opinions on the cement sales advertising plan and the division of cement sales areas. On this business trip, Yu Jianhong also specially brought Jinhua specialty ham and crisp cakes to the project team members, which were welcomed by everyone. (Lei Yuan)
2020
07-31
Since the resumption of work after the Spring Festival, on March 17, Yu Jian, general manager of the group company, went to the site of the Huangping project in Guizhou to guide the construction progress of the Huangping project. During his stay in Huang Ping, General Manager Yu Jianhong visited the construction site of the project carefully, interviewed the project leaders of each construction unit respectively, sorted out the installation time of each unit of civil engineering and the completion time of each equipment installation, and required each construction unit to push forward the project progress in strict accordance with the agreed time node. At the same time, in view of the current epidemic prevention and control work and on-site construction safety management, Yu Jianhong also further put forward requirements, hoping to achieve "zero infection, zero accident". On the 18th, Yu Jianhong also conducted a research on the market in Kaili and other surrounding areas together with the marketing personnel of Guizhou Jianfeng Marketing Department, and put forward guiding opinions on the cement sales advertising plan and the division of cement sales areas. On this business trip, Yu Jianhong also specially brought Jinhua specialty ham and crisp cakes to the project team members, which were welcomed by everyone. (Lei Yuan)
2020
07-31
Jinhua chain pharmacy big "physical examination" peak pharmacy got an "A"
Jinhua City Market Supervision Bureau recently announced the results of drug quality credit rating of drug retail chain enterprises in the city, and Jianfeng Pharmacy was rated as A in this "physical examination. According to the spirit of the document "Implementation Plan for Drug Quality Credit Classification Management of Jinhua Drug Trading Enterprises" and in accordance with relevant evaluation standards, Jinhua Market Supervision Bureau evaluated the 2019 drug quality credit rating of 34 drug retail chain enterprises (headquarters) in the city that met the evaluation requirements, involving 1498 stores. The score combines the daily supervision and inspection of chain headquarters, GSP certification inspection, administrative punishment and other drug quality-related information with the credit rating results of subordinate stores, and divides 100 into basic points, and forms the final score after adding and subtracting points according to the evaluation system. Those with 93 points or above are grade A (trustworthy enterprises),85-92 are grade B (basically trustworthy enterprises), and 80-84 are grade C (slightly dishonest enterprises), A score below 80 is Grade D (seriously dishonest enterprise). It is understood that the market supervision department will enter the enterprise credit rating evaluation results into the drug safety credit management system of Zhejiang Food and Drug Administration and Jinhua intelligent supervision and supervision platform to establish enterprise credit files. According to the credit rating evaluation results over the years, classified management will be carried out, and low-grade enterprises will increase the frequency of inspection. The "credit rating publicity board of drug trading enterprises" will be hung in the retail drugstore hall, and the evaluation results of the store will be publicized every year, let the people intuitively understand the credit situation of the store. At the same time, A- level enterprises are also the threshold for obtaining the qualification of designated medical insurance units, all kinds
2020
07-31
Daye Mayor to Daye Peak Research Issued "Anti-Epidemic" Donation Certificate
On the morning of March 26, Daye City Deputy Secretary, Mayor Zhou Jun and Daye City Economic and Information Bureau, Security Town and other responsible persons visited Daye Peak Cement Company to understand the epidemic prevention and control and resumption of production, and on behalf of the Daye City Charity Federation issued a certificate of donation of epidemic prevention and control materials. Accompanied by Zhang Fengliang, deputy general manager of the group company and general manager of Daye Peak, Yuan Xianming, executive deputy general manager of Daye Peak, and others, Zhou Jun and his entourage went to the work site of Daye Peak to learn about the resumption of work and production. Zhang Fengliang introduced the progress of the upgrading and transformation of the grate cooler, the transformation of the kiln cylinder and the technical transformation of the cement mill system, and made a detailed report on the production and technical transformation organization of the enterprise during the epidemic, and expressed his gratitude to Daye City and Baoan Town for their help to Daye Peak during this period. Mayor Zhou Jun spoke highly of the production and technological transformation organization during the Daye peak epidemic, believing that this is a model of combining epidemic prevention and control with enterprise production and technological transformation organization. At the same time, Zhou Jun expressed his affirmation and gratitude to Daye Peak for donating money and goods to Daye City in the first time after the outbreak of the epidemic, and issued a donation certificate and a letter of thanks on behalf of the Daye City Charity Federation. Hubei Province epidemic prevention and control headquarters has recently issued a step-by-step "unsealing" notice in Hubei Province, how to fully resume work and production as soon as possible is an important issue facing Daye peak. Zhang Fengliang reported to Zhou Jun and his party on the current practical difficulties. Mayor Zhou Jun asked
2020
07-31
Since the resumption of work after the Spring Festival, on March 17, Yu Jian, general manager of the group company, went to the site of the Huangping project in Guizhou to guide the construction progress of the Huangping project. During his stay in Huang Ping, General Manager Yu Jianhong visited the construction site of the project carefully, interviewed the project leaders of each construction unit respectively, sorted out the installation time of each unit of civil engineering and the completion time of each equipment installation, and required each construction unit to push forward the project progress in strict accordance with the agreed time node. At the same time, in view of the current epidemic prevention and control work and on-site construction safety management, Yu Jianhong also further put forward requirements, hoping to achieve "zero infection, zero accident". On the 18th, Yu Jianhong also conducted a research on the market in Kaili and other surrounding areas together with the marketing personnel of Guizhou Jianfeng Marketing Department, and put forward guiding opinions on the cement sales advertising plan and the division of cement sales areas. On this business trip, Yu Jianhong also specially brought Jinhua specialty ham and crisp cakes to the project team members, which were welcomed by everyone. (Lei Yuan)
2020
07-30
Contact Us
No. 88 Wujiang East Road, Jinhua City, Zhejiang Province, China
Tel: +86-579-82326868
Fax : +86-579-82324666
©2023 Zhejiang Jianfeng Group Co., Ltd. Powered by: www.300.cn SEO Business License
SAF Coolest v1.2 设置面板 SHJSS-AHDB-FSSQE-ZSW
无数据提示
Sorry, the current column has no content !
You can view other columns or return to Home Page